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Summary
Intensity modulated radia-
tion therapy (IMRT) has
been rapidly adopted despite
a lack of evidence demon-
strating superiority over 3D-
conformal radiation therapy
(3D-CRT). A national cohort
study using real-world data
was performed on 23,222
men comparing severe
gastrointestinal (GI) and
genitourinary (GU) toxicity
between IMRT and 3D-CRT.
Men who received radical
radiation therapy using
IMRT were less likely to
experience severe GI toxicity
and had similar GU toxicity
compared with those who
received 3D-CRT.
Purpose: To compare, in a national population-based study, severe genitourinary (GU)
and gastrointestinal (GI) toxicity in patients with prostate cancer who were treated
with radical intensity modulated radiation therapy (IMRT) or 3-dimensional conformal
radiation therapy (3D-CRT).
Methods and Materials: Patients treatedwith IMRT (nZ6933) or 3D-CRT (nZ16,289)
between January 1, 2010 and December 31, 2013 in the English National Health Service
were identified using cancer registry data, the National Radiotherapy Dataset, and Hos-
pital Episodes Statistics, the administrative database of care episodes in National Health
Service hospitals. We developed a coding system that identifies severe toxicity (at least
grade 3 according to the National Cancer Institute Common Terminology Criteria for
Adverse Events scoring system) according to the presence of a procedure and a corre-
sponding diagnostic code in patients’ Hospital Episodes Statistics records after radiation
therapy. A competing risks regression analysis was used to estimate hazard ratios (HRs),
comparing the incidence of severe GI and GU complications after IMRT and 3D-CRT,
adjusting for patient, disease, and treatment characteristics.
Results: The use of IMRT, as opposed to 3D-CRT, increased from3.1% in 2010 to 64.7%
in 2013. Patients who received IMRTwere less likely than those receiving 3D-CRT to
experience severe GI toxicity (4.9 vs 6.5 per 100 person-years; adjusted HR 0.66;
95% confidence interval 0.61-0.72) but had similar levels of GU toxicity (2.3 vs 2.4
per 100 person-years; adjusted HR 0.94; 95% confidence interval 0.84-1.06).
Conclusions: Prostate cancer patients who received radical radiation therapy using
IMRTwere less likely to experience severe GI toxicity, and they had similar GU toxicity
compared with those who received 3D-CRT. These findings in an unselected “real-
world” population support the use of IMRT, but further cost-effectiveness studies are ur-
gently required. 2017 TheAuthor(s). Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
Introduction
External beam radiation therapy (RT) is a well-established
definitive treatment for localized and locally advanced
prostate cancer. Dose-escalation to the tumor has been
shown to improve biochemical progression-free survival;
however, this can be at the cost of increased gastrointestinal
(GI) and genitourinary (GU) side effects (1-4). Gastroin-
testinal toxicity can occur in the acute phase typically
within 3 months, caused by a mucosal inflammatory
response, and in the late phase, characterized by fibrotic
changes resulting in chronic GI impairment (5). Similarly,
GU side effects such as hematuria can occur soon after
treatment, whereas bladder outflow obstruction and radia-
tion cystitis may occur later (6).
Attempts to improve the therapeutic ratio, in partic-
ular a reduction in treatment-related side effects, has
driven advances in modern RT technologies such as in-
tensity modulated radiation therapy (IMRT) (4). The
advantage of IMRT compared with 3-dimensional
conformal radiation therapy (3D-CRT) is the potential
to deliver high-dose radiation to the prostate (7, 8), while
limiting the radiation dose to surrounding tissue,
including the rectum and bladder, reducing acute and late
toxicities (9-12).
Intensity modulated radiation therapy was taken up
rapidly from the early 2000s in the United States and then in
the United Kingdom (13) at considerable cost (14) in the
absence of robust randomized controlled trial evidence
demonstrating its superiority over 3D-CRT (15). A recent
meta-analysis including 23 clinical studies with 9556 patients
demonstrated that the use of IMRT greatly reduced acute and
late GI toxicity (16). This also suggested that IMRT was
linked to a small increase in acute GU toxicity and a small
reduction in biochemical failure (ie, rise of prostate-specific
antigen level of 2 ng/mL or more). However, the authors of
this meta-analysis highlighted the heterogeneity of the results
and that more high-quality studies were needed.
The rapid adoption of IMRTmeans that future randomized
controlled trials assessing its effectiveness are no longer
feasible. However, “real-world” data provide an opportunity
to understand the truevalue of IMRTcomparedwith 3D-CRT.
We carried out a national population-based study including
more than 23,000 men diagnosed with prostate cancer
between 2010 and 2013 in the English National Health
Service, who received either IMRT or 3D-CRT. We used a
coding system that was specially developed to identify severe
toxicity, comparable to at least grade 3 toxicity as measured
by the National Cancer Institute Common Toxicity Criteria
for Adverse Events scoring system (version 4.0) (17), in
administrative hospital data.
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Methods and Materials
Data sources and patient population
English cancer registry data and the National Radiotherapy
Dataset were used to identify men with a diagnosis of
prostate cancer (International Classification of Diseases,
10th Revised Edition [ICD-10] “C61”) who received radical
RT between January 1, 2010 and December 31, 2013 (18).
These men were linked to the Hospital Episode Statistics
(HES) database, an administrative database of all care
episodes in the National Health Service in England (19).
Control variables
Data items in HES records were used to determine age, the
Royal College of Surgeons (RCS) Charlson comorbidity
score expressed as the number of comorbidities (20), and
socioeconomic deprivation status according to quintiles of
the national ranking of the Index of Multiple Deprivation
(21). Tumor characteristics, including TNM stage and
Gleason score, were extracted from the cancer registry data
to determine a modified D’Amico prostate cancer risk
classification (a previously developed algorithm to group
patients according to pretreatment prostate cancer risk in
the absence of data on prostate-specific antigen levels) (13).
The National Radiotherapy Dataset provided information
on the RT treatment region (prostate only/prostate and
regional), whether an IMRT technique was used (OPCS-4
code “X671”) (22), and the total prescribed dose/fractions.
Inclusion and exclusion criteria
The records of 41,763 men with nonmetastatic prostate
cancer who had received RT were studied. Patients were
excluded if they had also received brachytherapy (nZ165),
if they had an associated diagnosis of bladder cancer
(ICD-10 “C67”) (nZ1103) (23), or if they received RT
after radical prostatectomy (nZ3341). Because this study
used national data, variation existed in the fractionated
regimes delivered. With reference to United Kingdom RT
dose fractionation guidance and regimes used in random-
ized controlled trials (3, 24-27), we included patients who
received 72 to 79 Gy in 35 to 40 fractions. The 3 further
regimes that were most commonly used were also included
(72 Gy/32 fractions; 69 Gy/37 fractions; 70 Gy/35 frac-
tions). This resulted in the exclusion of a further 13,932
men. The final cohort included 23,222 men (Fig. 1).
Coding framework
We have previously developed and validated a method using
linked administrative data to identify severe GU complica-
tions after radical prostatectomy (28). This methodologic
approach was used to capture severe urinary complications
after RT. With reference to earlier studies that used procedure
codes to measure toxicity (11, 29, 30), a comprehensive list
of OPCS-4 procedure codes (22) related to GU complica-
tions after RT was prespecified (“forward coding”). We also
examined the most frequently occurring procedure codes in
records of day-case and in-patient hospital episodes after RT
and added these to the prespecified list if they were not
already included but likely to be related to GU complications
(“backward coding”) (Appendix, Table E1; available online
at www.redjournal.org).
The forward andbackward coding approachwas repeated to
identify ICD-10 diagnostic codes related to urinary complica-
tions. In addition to a “radiation-specific” code (N304, “irra-
diation cystitis”), we also captured other common side effects,
including hematuria, GU strictures, and urinary incontinence
(Appendix, Table E2; available online at www.redjournal.org).
The GU toxicity outcome measure was defined as the occur-
rence of both a procedure and corresponding GU diagnostic
code in a patient record after thefirst RT treatment session. This
approach confined our analyses to what were likely to be more
severe complications, comparable to at least grade 3 toxicity as
measured by National Cancer Institute Common Toxicity
Criteria for Adverse Events Scoring system (ie, requiring
hospital admission or procedural intervention) (17).
For GI toxicity after RT, we also determined a list of
procedure and diagnostic codes based on previous studies
(Appendix, Tables E3 and E4; available online at www
.redjournal.org) (11, 29, 30). The ICD-10 diagnostic codes
included “radiation-specific” codes (K520 “gastroenteritis
and colitis due to radiation”; K627 “radiation proctitis”) as
well as those likely to be a GI complication of radiation, such
as rectal bleeding and fistulae formation (Appendix, Table
E4; available online at www.redjournal.org). Just as for GU
toxicity, we defined the GI toxicity outcome measure, also
capturing grade 3 or higher toxicity, as the occurrence of both
a procedure and corresponding GI diagnosis code to be
present in a patient record. This was important because it
excluded men who underwent procedures such as a “colo-
noscopy” for other reasons not related to post-RTGI toxicity.
Time from date of the first RT treatment to the first GU
or GI complication requiring an intervention were the study
primary outcomes. For both outcomes, if more than one
procedure code matched to a corresponding diagnosis code
in the patient record, then the code in the first procedural
field was used because it was most likely to represent the
most relevant procedure. Patients were considered as not
having experienced GU or GI toxicity if there were no day-
case or in-patient hospital episodes from the first date of RT
until the end of follow-up (December 31, 2015).
Statistical analysis
Differences between patient, disease, and treatment char-
acteristics were assessed using the c2 test. The 5-year cu-
mulative incidence of complications was estimated using a
competing-risks approach (31). To be consistent with
existing literature (32), for each outcome measure we
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calculated the number of events per 100 person-years of
follow-up. This metric provided a single figure for the rate
of GU and GI complications in both groups.
A competing-risks regression analysis was used to
compare time to complication between IMRT and 3D-CRT
groups,with complication as the event of interest and death as
the competing event. We adjusted for year of RT, age, RCS
Charlson comorbidity score, socioeconomic deprivation
status, prostate cancer risk group, and RT treatment region.
Results are reported as adjusted hazard ratios (HRs) with
95% confidence intervals (CIs). A P value <.05 was
considered statistically significant. P values were based on
the Wald test or the likelihood ratio test, as appropriate.
Before the regression analysis, missing values for pros-
tate cancer risk group (nZ5753), RT treatment region
(nZ3793), and socioeconomic deprivation status (nZ61)
were imputed using multiple imputation by chained equa-
tions. We created 50 datasets and used Ruben’s rules to
combine the estimated HRs across the datasets (33). The
distribution of patients in categories did not change
significantly after multiple imputation.
Results
Patient population
Among the patients who received radical RT (nZ23,222),
the use of IMRT increased from 3.1% in 2010 to 64.7% in
2013 (Table 1). Approximately 60% of men included were
between 65 and 74 years old, approximately 1 in 5 men
had at least 1 recorded comorbidity, and nearly 60% of
patients were staged with locally advanced disease. The
median dose per fraction and total dose received were the
same in both groups (2 Gy per fraction and 74 Gy,
respectively). Men in the 3D-CRT group were more likely
to be older and have an RCS Charlson score 1 but were
less likely to have locally advanced disease and receive
radiation to the prostate and nodes compared with the
IMRT group (Table 1). Median (interquartile range)
follow-up was 3.6 (1.9) years for all men in the study; 2.7
(1.0) years for the IMRT group and 4.1 (1.6) years for the
3D-CRT group.
Included fractionated regimes:
Regimen (Dose (Gy)/Fractions) No. of patients
72-79/35-40 21,046
72/32 1439
70/35 443
69/37 294
Radical radiotherapy
cohort
23,222 
Clinical exclusions (n=18,541) 
 165 men excluded who also
received brachytherapy 
 1,103 men excluded with
additional diagnosis of bladder
 3,341 men who received
radiotherapy after radical
prostatectomy 
 13,932  men excluded who did not
receive a recognised fractionated
regime* 
Men receiving radical radiotherapy (2010-2013)
(non-metastatic prostate cancer)
41,763 
Fig. 1. Flow chart of men included in study.
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Timing and frequency of occurrence of toxicity
The most frequent intervention for GI toxicity was a
“diagnostic fiber optic sigmoidoscopy” (3607 of 9300
procedures, 38.8%), and the commonest associated GI
diagnosis was “radiation proctitis” (5962 of 8701 di-
agnoses, 68.5%). For GU toxicity, an “unspecified endo-
scopic examination of the bladder” (1470 of 3625
procedures, 40.6%) was the most frequent intervention, and
“hematuria” was the most common associated GU diag-
nosis (1265 of 4061 diagnoses, 31.1%) (Appendix, Tables
E1-E4; available online at www.redjournal.org).
Patients experienced 4.9 GI events per 100 person years
of follow-up in the IMRT group, compared with 6.5 in the
3D-CRT group (Table 2). Patients who received IMRT
experienced 2.3 GU events per 100 person years of follow-
up, compared with 2.4 in the 3D-CRT group (Table 2).
Cumulative incidence curves showed GI toxicity was
low in the first 9 months (approximately 2%) and similar in
the IMRT and 3D-CRT groups (Fig. 2). However, beyond
9 months after RT, patients in the 3D-CRT group more
frequently had complications than the IMRT group.
Conversely, GU toxicity steadily increased in both IMRT
and 3D-CRT groups after radical RT (Fig. 2).
Outcome measures
Adjusting for patient, disease, and treatment characteristics
and using a competing-risks approach, we found that men
treated with IMRT were less likely to experience GI
toxicity (HR 0.66; 95% CI 0.61-0.72; P<.01) than those
who received 3D-CRT. There was no significant difference
in GU toxicity between the groups (HR 0.94; 95% CI
0.84-1.06; PZ.31) (Table 2) (Appendix, Table E5;
competing-risks regression analysis with all variables,
available online at www.redjournal.org).
Discussion
Summary
Using outcome measures that were systematically devel-
oped, we demonstrated a significantly lower incidence of
Table 1 Patient, disease, and treatment characteristics of men receiving radical radiation therapy
Characteristic 3D-CRT (nZ16,289) IMRT (nZ6933) P
Year of radiation therapy <.01
2010 4248 (26.1) 216 (3.1)
2011 5159 (31.7) 624 (9.0)
2012 4678 (28.7) 1605 (23.1)
2013 2204 (13.5) 4488 (64.7)
Age (y) <.01
<60 1069 (6.5) 532 (7.7)
60-64 2409 (14.8) 1096 (15.8)
65-74 9311 (57.2) 3879 (56.0)
>75 3500 (21.5) 1426 (20.6)
RCS Charlson comorbidity score <.01
0 12,407 (76.2) 5463 (78.8)
1 3882 (23.8) 1470 (21.2)
Socioeconomic deprivation status (national quintiles) .19
1 (least deprived) 3683 (22.6) 1649 (24.0)
2 4063 (25.0) 1735 (25.2)
3 3552 (21.8) 1471 (21.4)
4 2707 (16.6) 1112 (16.2)
5 (most deprived) 2270 (14.0) 919 (13.4)
Missing 14 47
Prostate cancer risk group <.01
Locally advanced 6433 (56.4) 3603 (59.4)
Intermediate risk localized 4433 (38.9) 2211 (36.4)
Low risk localized 534 (4.7) 384 (5.3)
Missing 4889 864
Radiation therapy treatment region <.01
Prostate 11,782 (72.3) 5786 (86.4)
Prostate and regional 950 (5.8) 911 (13.6)
Missing 3557 236
Abbreviations: 3D-CRT Z 3-dimensional conformal radiation therapy; IMRT Z intensity modulated radiation therapy; RCS Z Royal College of
Surgeons.
Values are number (percentage).
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severe GI toxicity and a similar incidence of severe GU
toxicity in men who received IMRT compared with those
who received 3D-CRT. This is the largest study comparing
treatment-related complications in patients receiving IMRT
or 3D-CRT. It used “real-world” data from a national
population-based cohort without excluding patients ac-
cording to age or socioeconomic status.
We have used outcome measures specifically designed
to capture urinary complications severe enough to require
an intervention and comparable to at least grade 3 toxicity
(National Cancer Institute Common Toxicity Criteria for
Adverse Events scoring system). This is in contrast to all
other studies using existing routine data (11, 34, 35) that
used discrete diagnosis, procedure, and claims codes
without explicitly developing these codes as toxicity out-
comes measures for a specific level of severity. A further
strength of our study was the availability of data on radi-
ation doses and fractions received by patients within the
National Radiotherapy Dataset, which was not present in
previous studies (8, 11, 30). This ensured that only
recognized fractionated regimes were included and that
patients in both IMRT and 3D-CRT groups received com-
parable radiation doses, which are often confounders in
population-based studies.
Comparison with other studies
The previous largest comparative study of IMRTand 3D-CRT
using existing routine data reported on approximately 13,000
men who received treatment between 2002 and 2006 (11), on
the basis of Surveillance, Epidemiology, and End
ResultseMedicare-linked data. Similar to our study findings,
men who received IMRTwere less likely to have GI toxicity,
and therewas no difference between the groups inGU toxicity.
This study found a higher incidence of GI toxicity after
3D-CRT than after IMRT when considering GI diagnoses in
both groups, but this was not the case when considering GI
procedures. This discrepancy is to be expected given the use of
toxicity based on diagnosis codes and procedure codes in
Table 2 Adjusted outcomes for gastrointestinal (GI) and genitourinary (GU) toxicity after radical radiation therapy
Therapy
GI toxicity GU toxicity
5-y cumulative
incidence (%)
(95% CI)
Rate (total
events/100
person years) HR* (CI) P
5-y cumulative
incidence (%)
(95% CI)
Rate (total
events/100
person-years) HR* (CI) P
3D-CRT 24.5 (23.8-25.3) 6.5 1.00 - 11.1 (9.2-13.3) 2.4 1.00 -
IMRT 17.0 (15.6-18.5) 4.9 0.66 (0.61-0.72) <.01 10.7 (10.1-11.3) 2.3 0.94 (0.84-1.06) .31
Abbreviations: CI Z confidence interval; HR Z hazard ratio. Other abbreviations as in Table 1.
* Adjusted for year of radiation therapy treatment, age, RCS Charlson comorbidity score, socioeconomic deprivation status, prostate cancer risk group,
and radiation therapy treatment region.
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Fig. 2. Cumulative incidence curves for gastrointestinal toxicity (A) and genitourinary toxicity (B) after radical radiation
therapy according to type of radiation therapy (intensity modulated radiation therapy [IMRT] vs 3-dimensional conformal
radiation therapy [3D-CRT]).
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isolation. In contrast, our study required the presence of a
diagnosis and procedure code to ensure we captured compli-
cations comparable to grade 3 toxicity or higher.
Our findings are similar to those reported in a recent meta-
analysis (16), which found that IMRT had a lower incidence
of acute and late GI toxicity. This meta-analysis also found a
very small increase in acute GU toxicity after IMRT, which
was not observed in our study. It is important to note that in
most of the studies included in the meta-analysis, patients in
the IMRT group received a higher total radiation dose than
those in the 3D-CRT group. A strength of our study is that
both groups received comparable radiation doses.
We adjusted the comparison of the incidence of compli-
cations in men who received IMRT or 3D-CRT for differ-
ences in patient, disease, and treatment characteristics.
However, wewere not able to control for baseline GI and GU
symptoms that could have an impact on post-RT toxicity.
Furthermore, we could not control for additional therapeutic
differences, including the use of image-guided radiation
therapy, the use of specific bladder or bowel preparation
protocols, RTfield size, or the use of hormonal treatment. For
example, the use of image-guided radiation therapy reduces
GI and GU toxicity (36) and is more likely to have been used
in IMRT patients. If this is the case, our study may have
overestimated the relative benefit of IMRT. Information on
the use of hormonal therapy was also not available, although
results from previous studies demonstrate that hormonal
therapy was not associated with the incidence of GI or GU
toxicity (16, 37). Despite the absence of information on RT
field size, we were able to account for whether men received
treatment to the prostate alone or to the whole pelvis. At the
time of this study the last follow-up date within our database
was the December 31, 2015; therefore, we were not able to
report on longer-term GI and GU toxicitydfuture studies
will aim to address longer-term RT-related toxicity.
Because the use of IMRT compared with 3D-CRT
increased during our study period, the median length of
follow-up was higher in the latter. Although we adjusted for
year of treatment in the regression model, we also per-
formed a sensitivity analysis only including men who
received RT in 2012 and 2013, all of whom had at least
2-years of follow-up. The results of this sensitivity analysis
fully supported the findings from the primary analysis.
Clinical implications
Our findings are in line with the notion that IMRT allows
the delivery of higher doses while reducing exposure to the
rectum and in turn reducing GI toxicity. Furthermore, this
reduction occurred despite a higher proportion of patients
in the IMRT group receiving additional pelvic RT
compared with the 3D-CRT group. The benefits of IMRT,
however, do not seem to lead to a reduction in GU toxicity.
A potential explanation for this is that the benefits of IMRT
may be countered by the high variability in patients’
bladder capacity and filling volumes. These findings are
supported by other dosimetric studies, which have shown
that rectal sparing is better with IMRT than with 3D-CRT
but that the differences for bladder sparing may not be as
significant (8, 38).
Given the substantial increased costs associated with
delivering IMRT (39), further studies are required to eval-
uate the cost-effectiveness of IMRT in light of its improved
toxicity profile with respect to severe GI toxicity. This is of
particular relevance in low- and middle-income countries
where there is an urgent need for expansion in access to RT
(40). The lack of robust comparative clinical data has meant
that the benefit from IMRT in a cost-effectiveness model
remains uncertain, particularly the estimation of the inci-
dence of toxicity after treatment (41). The morbidity out-
comes from our study provide further means to strengthen
economic models using existing administrative data.
Conclusion
In this national population-based study of patients with
nonmetastatic prostate cancer, we have shown that men
who received radical RT using IMRT were less likely to
experience severe GI toxicity and that they had similar
severe GU toxicity compared with those who received 3D-
CRT. Our study used a transparent coding system that was
specifically developed to identify only severe complica-
tions. This coding system can be used to provide a per-
formance indicator for service evaluation and quality
assessment. Furthermore, it can be used for comparative
effectiveness research using existing administrative data to
capture GU and GI toxicity after pelvic-based RT of other
tumors, such as cervical cancer.
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